目录产品 » IL-18BP, His, Mouse

IL-18BP, His, Mouse

Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice.
¥1300
Z06194-100

Species Mouse
Protein Construction
IL-18BP (Thr29-Ala193)_x000D_
Accession # Q9Z0M9
His
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized IL-18BP, His, Mouse at 1μg/ml (100μl/well) on the plate can bind Biotinylated IL­18, No Tag. Test result was comparable to standard batch
Expression System HEK293
Theoretical Molecular Weight 19.1 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 45-65 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.
返回

IL-18BP, His, Mouse

Immobilized IL-18BP, His, Mouse, His Tag at 1 μg/ml(100 μl/well) on the plate. Dose response curve for Biotinylated Human IL-18, No Tag with the EC50 of 21.5 ng/ml determined by ELISA. »

IL-18BP, His, Mouse

IL-18BP, His, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

IL-18BP, His, Mouse

IL-18BP, His, Mouse, His Tag captured on CM5 Chip via anti-his antibody can bind Human IL-18, No Tag with an affinity constant of 0.86 nM as determined in SPR assay (Biacore T200). »

<
>

Target Background Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice.
Synonyms IL-18BP; Igifbp
返回

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.